Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response to therapy. We aimed to comprehensively characterise the spatial im-mune phenotypes in the mutational and clinicopathological background of non-small cell lung cancer (NSCLC). Methods: We established a multiplexed fluorescence imaging pipeline to spatially quantify 13 immune cell subsets in 359 NSCLC cases: CD4 effector cells (CD4-Eff), CD4 regulatory cells (CD4-Treg), CD8 effector cells (CD8-Eff), CD8 regulatory cells (CD8-Treg), B-cells, natural killer cells, natural killer T-cells, M1 macrophages (M1), CD163 thorn myeloid cells (CD163), M2 macrophages (M2), immature dendritic cells (iDCs), mature dendritic cells (mDCs) and plasmacytoid de...
Immune checkpoint inhibitor therapy holds therapeutic promise for patients with cancer. Yet, its ef...
The composition and activation status of the cellular milieu contained within the tumour microenviro...
Introduction: Spatial distribution of immune cells within the tumor immune microenvironment (TIME) i...
Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response...
OBJECTIVES: Tumour-infiltrating lymphocytes (TILs) are critically implicated in the clinical outcome...
Abstract Background The tumor microenvironment (TME) is a complex mixture of tumor epithelium, strom...
Nasopharyngeal cancer (NPC) is a malignant tumor. In a recent publication, we described the presence...
Cancer is a leading cause of premature death and lung cancer is the deadliest cancer type, with non-...
Please see the newest version. A dataset with spatial immune cell information on a lung cancer cohor...
BackgroundThe anti-tumoral or pro-tumoral roles of CD4+ and CD8+ T cells typify the complexity of T ...
Lung cancer is the fourth most prevalent cancer in Norway, holding first place in mortality rate. No...
The impacts of the tumor microenvironment (TME) on tumor evolvability remain unclear. A challenge fo...
Background: Profiling the tumour microenvironment (TME) has been informative in understanding the un...
Lung cancer is the leading cause of cancer-associated death worldwide. To improve clinical managemen...
A dataset with spatial immune cell information on a lung cancer cohort from Uppsala University Hospi...
Immune checkpoint inhibitor therapy holds therapeutic promise for patients with cancer. Yet, its ef...
The composition and activation status of the cellular milieu contained within the tumour microenviro...
Introduction: Spatial distribution of immune cells within the tumor immune microenvironment (TIME) i...
Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response...
OBJECTIVES: Tumour-infiltrating lymphocytes (TILs) are critically implicated in the clinical outcome...
Abstract Background The tumor microenvironment (TME) is a complex mixture of tumor epithelium, strom...
Nasopharyngeal cancer (NPC) is a malignant tumor. In a recent publication, we described the presence...
Cancer is a leading cause of premature death and lung cancer is the deadliest cancer type, with non-...
Please see the newest version. A dataset with spatial immune cell information on a lung cancer cohor...
BackgroundThe anti-tumoral or pro-tumoral roles of CD4+ and CD8+ T cells typify the complexity of T ...
Lung cancer is the fourth most prevalent cancer in Norway, holding first place in mortality rate. No...
The impacts of the tumor microenvironment (TME) on tumor evolvability remain unclear. A challenge fo...
Background: Profiling the tumour microenvironment (TME) has been informative in understanding the un...
Lung cancer is the leading cause of cancer-associated death worldwide. To improve clinical managemen...
A dataset with spatial immune cell information on a lung cancer cohort from Uppsala University Hospi...
Immune checkpoint inhibitor therapy holds therapeutic promise for patients with cancer. Yet, its ef...
The composition and activation status of the cellular milieu contained within the tumour microenviro...
Introduction: Spatial distribution of immune cells within the tumor immune microenvironment (TIME) i...